FIB-4 Calculator for Liver Fibrosis Risk Screening

Fibrosis signal junction

FIB-4 Calculator

Combine age, AST, ALT, and platelet count into the Fibrosis-4 index, then route the arithmetic through an age- and condition-specific interpretation pathway. Thresholds remain separate from the score so a historical HIV/HCV rule is not silently applied to MASLD.

FIB-4 is a risk-stratification tool, not a fibrosis stage. It cannot diagnose cirrhosis, replace elastography or biopsy, or evaluate acute liver injury. AASLD cautions against using FIB-4 interpretation in acutely ill patients and notes low accuracy under age 35.

Enter same-date clinical data

A U.S. report of 180 K/µL is numerically 180 ×10⁹/L. Do not enter 180,000.

FIB-4 result

Fibrosis-4 index2.17Intermediate MASLD pathway—secondary assessment
lower boundary 1.30higher boundary 2.67
Age55
AST45 U/L
√ALT6.325
Platelets180 ×10⁹/L
Equation numerator2,475
Equation denominator1,138.4
Distance above lower boundary0.87
Distance below upper boundary0.50
Platelets at lower boundary*301 ×10⁹/L
Platelets at upper boundary*147 ×10⁹/L
Interpretation active

Under the selected MASLD pathway and age, this score supports secondary noninvasive assessment rather than assigning a fibrosis stage.

*Arithmetic scenario holding age, AST, and ALT fixed—not a platelet target.

What FIB-4 is designed to answer

FIB-4 is a noninvasive index derived from four routinely available variables: age, aspartate aminotransferase, alanine aminotransferase, and platelet count. It was initially developed in people with HIV and hepatitis C coinfection to help identify advanced liver fibrosis without immediately performing biopsy.

Later studies evaluated different thresholds in metabolic dysfunction-associated steatotic liver disease, previously called NAFLD. AASLD uses FIB-4 as a first-line risk stratification step because a low result can help identify many patients less likely to have advanced fibrosis, while an intermediate or higher result routes patients toward a second test.

“Risk stratification” is the key phrase. FIB-4 does not output histologic stage F0 through F4. Age can raise the score even without worsening liver disease, low platelets can arise from many causes, and aminotransferases can fluctuate. A result needs the clinical pathway for the suspected liver condition.

Equation and units

FIB-4 = (age in years × AST in U/L) ÷ (platelets in 10⁹/L × square root of ALT in U/L)

U.S. complete blood counts often report platelets as K/µL. That number is numerically equal to ×10⁹/L: 180 K/µL is entered as 180. Entering 180,000 would produce a result one thousand times too low. AST and ALT should be contemporaneous with the platelet count when possible.

Age is in the numerator, which creates an age effect independent of biology. ALT appears under a square root, so a change in ALT does not move the denominator linearly. Platelet count is directly in the denominator; lower platelets raise FIB-4.

The optional platelet-boundary outputs rearrange the same equation: platelets = age × AST ÷ (boundary × √ALT). They show how the selected cutoffs relate to the current numbers. They are not a goal, prediction, or suggestion to alter platelets.

Worked example: FIB-4 of 2.17

  1. Use the same date. Age is 55, AST 45 U/L, ALT 40 U/L, and platelets 180 ×10⁹/L.
  2. Build numerator. Fifty-five multiplied by 45 equals 2,475.
  3. Build denominator. The square root of 40 is 6.325; multiplied by 180 it is about 1,138.4.
  4. Divide. 2,475 divided by 1,138.4 equals approximately 2.17.
  5. Select pathway. For MASLD at age 55, 2.17 lies between 1.30 and 2.67.

The result is routed to an intermediate pathway where AASLD guidance supports secondary assessment, such as vibration-controlled transient elastography or an Enhanced Liver Fibrosis test, depending on availability and context. It does not mean “stage 2.17” and does not establish advanced fibrosis.

Thresholds change with pathway and age

Selected pathwayLower boundaryHigher boundaryMeaning
AASLD MASLD, age 35–651.302.67Below lower is a lower-risk first step; middle needs secondary assessment; above higher increases concern.
AASLD MASLD, older than 652.002.67Higher lower cutoff reduces false positives from age; higher boundary remains 2.67.
MASLD, under 35Low accuracyDo not rely on band aloneAASLD recommends considering secondary assessment based on metabolic risk and liver tests.
Original HIV/HCV framework1.453.25Historical derivation thresholds; not automatically transferable to MASLD.

A cutoff is not a biological cliff. Measurement variation can move a result near a boundary. Trends, etiology, diabetes, metabolic risk, alcohol history, medications, viral testing, examination, imaging, and specialist judgment remain relevant.

Why acute illness locks interpretation

Aminotransferases may rise sharply with acute viral hepatitis, ischemia, medication injury, biliary disease, muscle injury, or another acute process. Platelets can fall during infection, inflammation, consumption, hemodilution, or critical illness. Feeding those transient values into a chronic-fibrosis pathway can make FIB-4 look high for the wrong reason.

AASLD practice guidance states that FIB-4 should not be used in acutely ill patients. The calculator still shows arithmetic when the acute box is selected so data entry can be audited, but replaces the band with an interpretation lock. Clinical evaluation of the acute condition takes priority.

Normal AST and ALT do not rule out advanced fibrosis either. The index is a pathway tool, not an all-purpose liver screen. People with risk factors may need assessment even when aminotransferases fall within a laboratory reference interval.

What secondary assessment can add

Elastography

Vibration-controlled transient elastography or magnetic resonance elastography estimates liver stiffness, answering a different question from blood values. Congestion and inflammation can still affect stiffness.

Blood panels

ELF and other validated tests combine additional biomarkers. Availability, payer rules, and intended population matter.

Specialist review

Hepatology can integrate cause, imaging, portal-hypertension signs, medications, comorbidity, and whether biopsy would change management.

Do not self-order a surveillance or treatment plan from the FIB-4 number. Even a higher result may be a false positive, while a lower result can miss disease. A pathway balances those errors by combining sequential tests.

Understand what makes the number change

FIB-4 can fall because AST falls, age cannot fall, ALT rises under the square root, or platelets rise. Those mathematical directions do not all mean fibrosis improved. For example, ALT may decline in advanced liver disease, and platelet count can change with infection, medication, immune conditions, laboratory variation, or spleen size.

Conversely, a rising score may reflect an acute AST increase rather than scar progression. Always compare the source values, collection dates, symptoms, and clinical setting. Saving only “FIB-4 2.2” removes the information needed to explain why it changed.

Age moves slowly but can shift someone across a boundary without any new laboratory result. At the 65-year transition, the MASLD lower threshold also changes in many pathways. Software should therefore store the selected guidance and age rule, not merely apply one color forever.

The platelet scenarios in the result panel are sensitivity calculations. They show the platelet value that would place the current age, AST, and ALT exactly on a cutoff. They do not estimate a future platelet count and must never be used as a treatment target.

Reassessment belongs to a risk-based care pathway

AASLD pathways use different reassessment intervals depending on diabetes and the number of metabolic risk factors. That schedule can change with a new diagnosis, worsening laboratory trend, medication exposure, alcohol intake, weight change, or another liver condition. This calculator intentionally does not generate a calendar date.

Repeat testing should answer a clinical question and ideally use comparable laboratory conditions. A clinician may first confirm unexpected thrombocytopenia or aminotransferase elevation, investigate another cause, or wait until an acute illness resolves. Repeating the same arithmetic without resolving bad input does not add certainty.

People with diabetes, multiple metabolic risk factors, persistently elevated liver tests, imaging evidence of steatosis, or a concerning secondary test may need more frequent review or referral. A low first-step score is not permission to ignore the underlying metabolic and cardiovascular risks associated with MASLD.

Data-quality and scope checklist

Use completed age on the laboratory date, not current age when reviewing an old panel. Confirm that platelet units are K/µL or ×10⁹/L and that AST and ALT are U/L. Avoid mixing values from different episodes.

FIB-4 is not validated as a pediatric score. It is not a substitute for hepatitis testing, alcohol-use assessment, medication review, iron studies, autoimmune evaluation, or imaging when indicated. The selected MASLD thresholds should not be copied to every liver disease.

Seek prompt medical assessment for jaundice with illness, confusion, vomiting blood, black stools, severe abdominal swelling, fainting, or another emergency. This calculator cannot assess liver failure or portal-hypertension complications.

Frequently asked questions

Is FIB-4 a fibrosis stage?

No. It is a probability-oriented risk index. It does not map directly to biopsy stages F0–F4.

Why is the cutoff 2.0 after age 65?

Age raises FIB-4 and reduces specificity in older adults. AASLD MASLD pathways use a higher lower boundary to reduce age-related false positives.

Can I calculate it during acute hepatitis?

The arithmetic exists, but chronic-fibrosis interpretation is unreliable. The calculator locks the band when acute illness is selected, consistent with AASLD caution.

What platelet unit should I enter?

Enter the numeric K/µL value used on many U.S. reports. For example, 180 K/µL equals 180 ×10⁹/L and is entered as 180.

Does a low result rule out all liver disease?

No. It may lower the probability of advanced fibrosis in the selected pathway, but does not exclude steatosis, inflammation, early fibrosis, another liver disease, or every advanced case.

How often should FIB-4 be repeated?

Frequency depends on diabetes, metabolic risk, known liver disease, previous results, and current guidance. Follow the clinician’s pathway rather than an automatic web schedule.

Related planning context

For a separate U.S. It does not determine medical deductions or liver care.

References

Educational use only. Use current disease-specific guidance and qualified clinical interpretation.

Scroll to Top